EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Evox Therapeutics landed a deal with Takeda. The agreement will see Takeda pay up to $44 million (€40 million) in upfront fees, near-term milestones and research funding in return for access to up to five protein replacement and mRNA therapies. Release  

> Synairgen raised £14 million to run a COVID-19 trial. The British biotech recently got clearance to test its inhaled formulation of interferon-beta-1a in patients with the coronavirus. Statement

> AstraZeneca expanded its collaboration with Schrödinger. The new deal covers biologics, not just small molecules. Release 

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

> Vaccitech and the University of Oxford shared phase 2a data on prostate cancer immunotherapy VTP-800. Based on early evidence that VTP-800 enhances the efficacy of checkpoint inhibitors, the British biotech plans to move the candidate into a larger midphase trial. Statement  

> Themis joined a collaborative effort to develop a vaccine against COVID-19. The Institut Pasteur is leading the consortium. Release 

> Freeline appointed Julie Krop as chief medical officer. Krop has previously worked at companies including Pfizer and Vertex. Statement 

Suggested Articles

Takeda and CSL Behring have set up an alliance work on an unbranded treatment made from the plasma of patients who have recovered from COVID-19.

In this week's EuroBiotech Report, AstraZeneca, GSK share COVID-19 updates, Wellcome sounds alarm on panedmic funding and Evotec. 

In our EuroBiotech roundup this week, MorphoSys pauses MOR202 trial, Oryzon posts Alzheimer’s data and Kite-partner Gadeta hires CEO.